<DOC>
	<DOCNO>NCT02221882</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug know LY3164530 participant cancer advance and/or spread another part ( ) body .</brief_summary>
	<brief_title>A Study LY3164530 Participants With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Inclusion Criteria Have advance metastatic cancer appropriate candidate experimental therapy . Have adequate organ function . Prior Treatments : Systemic treatment : Must discontinue previous systemic treatment cancer recover acute effect therapy . Participants must discontinue : Cytotoxic therapy target agent small molecule inhibitor 5 halflives least 28 day . MitomycinC nitrosourea therapy least 42 day biologic agent least 28 day . Radiation therapy surgery must complete 4 week prior therapy , except limited field radiation therapy , must complete 2 week therapy . If participant reproductive potential , must agree use medically approve contraceptive precaution study three month follow last dose study drug . If participant female childbearing potential , must negative serum urine pregnancy test within 14 day first dose study drug must breast feeding . Must take unapproved drug treatment indication within last 28 day prior start study treatment . Must active symptomatic fungal , bacterial viral infection , include human immunodeficiency virus ( HIV ) Hepatitis A , B , C. Must serious preexist medical condition concomitant disorder . Must leukemia . Must QT interval &gt; 470 millisecond . Must serious cardiac condition , congestive heart failure , unstable angina pectoris , heart attack within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>